Skip to main content
Top
Published in: Supportive Care in Cancer 10/2014

Open Access 01-10-2014 | Original Article

A cross-sectional survey of the diagnosis and management of bone metastasis in breast cancer patients in Turkey

Authors: Ali Arican, Tulin Bozkurt, Hakan Bozcuk, Binnaz Demirkan, Suleyman Buyukberber, Necati Alkis, Ulus Ali Sanli, Celalettin Camci, Mustafa Yildiz, Idris Yucel, Kazim Uygun, Isik Aslay, Mutlu Demiray, Nuran Senel Bese, Abdurrahman Isikdogan, Zumrut Bahat, Cengiz Gemici, Feyyaz Ozdemir, Fatih Ozdener, Bahadir Pekin

Published in: Supportive Care in Cancer | Issue 10/2014

Login to get access

Abstract

Purpose

This study aimed to report the practice of managing breast cancer with bone metastasis in Turkey and to determine the adherence to the British Association of Surgical Oncology (BASO) guidelines.

Methods

This multicenter, cross-sectional epidemiological survey was conducted in 38 centers across Turkey. Data from 1,026 breast cancer patients with bone metastases (mean age 54.0 ± 11.9 years) were analyzed.

Results

Over 30 % of patients had a diagnosis of metastatic breast cancer (stage IV) at the time of primary diagnosis. The imaging modalities used for diagnosing bone metastases were bone scintigraphy (57.8 %), radiography (22.8 %), and bone survey (4.4 %). Tumor markers were detected in 94.9 %, and markers of bone metabolism were measured in 90.4 % of patients. A total of 3.5 % of patients underwent surgery for bone metastasis, 26.4 % underwent palliative chemotherapy (most commonly docetaxel + capecitabine), and 56.5 % endured radiotherapy. Most patients (96 %) also received bisphosphonate. Radiography, bone scintigraphy, and CT were the main imaging tools used for postoperative follow-up of bone metastasis. Our results were >95 % in line with the BASO guidelines for the management of bone metastasis, except that interventional procedures, such as biopsy, were applied less frequently in our survey.

Conclusions

The diagnosis and management practices of breast cancer with bone metastasis in Turkey were generally compatible with international guidelines. However, the awareness and knowledge of physicians on the current guidelines should be increased, and equipment for the appropriate interventional procedures should be provided in every clinic to obtain optimal and standard management of bone metastases.
Literature
3.
go back to reference Coleman RE (2001) Metastatic bone disease: clinical features, pathophysiology, and treatment strategies. Cancer Treat Rev 27:165–176PubMedCrossRef Coleman RE (2001) Metastatic bone disease: clinical features, pathophysiology, and treatment strategies. Cancer Treat Rev 27:165–176PubMedCrossRef
4.
5.
go back to reference Giordano SH, Buzdar AU, Smith TL et al (2004) Is breast cancer survival improving? Cancer 100:44–52PubMedCrossRef Giordano SH, Buzdar AU, Smith TL et al (2004) Is breast cancer survival improving? Cancer 100:44–52PubMedCrossRef
6.
go back to reference Chia SK, Speers CH, D’yachkova Y et al (2007) The impact of new chemotherapeutic and hormone agents on survival in a population-based cohort of women with metastatic breast cancer. Cancer 110:973–979PubMedCrossRef Chia SK, Speers CH, D’yachkova Y et al (2007) The impact of new chemotherapeutic and hormone agents on survival in a population-based cohort of women with metastatic breast cancer. Cancer 110:973–979PubMedCrossRef
7.
go back to reference Pagani O, Senkus E, Wood W et al (2010) ESO-MBC Task Force. International guidelines for management of metastatic breast cancer: can metastatic breast cancer be cured? J Natl Cancer Inst 102:456–463PubMedCentralPubMedCrossRef Pagani O, Senkus E, Wood W et al (2010) ESO-MBC Task Force. International guidelines for management of metastatic breast cancer: can metastatic breast cancer be cured? J Natl Cancer Inst 102:456–463PubMedCentralPubMedCrossRef
8.
go back to reference Goldhirsch A, Wood WC, Coates AS et al (2011) Panel members. Strategies for subtypes dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer. Ann Oncol 22:1736–1747PubMedCentralPubMedCrossRef Goldhirsch A, Wood WC, Coates AS et al (2011) Panel members. Strategies for subtypes dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer. Ann Oncol 22:1736–1747PubMedCentralPubMedCrossRef
9.
go back to reference National Comprehensive Cancer Network (2012) NCCN clinical practice guidelines for breast cancer, version I. Available from: www.nccc.org National Comprehensive Cancer Network (2012) NCCN clinical practice guidelines for breast cancer, version I. Available from: www.​nccc.​org
10.
go back to reference Harris L, Fritsche H, Mennel R et al (2007) American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol 25:5287–5312PubMedCrossRef Harris L, Fritsche H, Mennel R et al (2007) American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol 25:5287–5312PubMedCrossRef
11.
go back to reference British Association of Surgical Oncology Guidelines (1999) The management of metastatic bone disease in the United Kingdom. The Breast Specialty Group of the British Association of Surgical Oncology. Eur J Surg Oncol 25:3–23CrossRef British Association of Surgical Oncology Guidelines (1999) The management of metastatic bone disease in the United Kingdom. The Breast Specialty Group of the British Association of Surgical Oncology. Eur J Surg Oncol 25:3–23CrossRef
12.
go back to reference Cardoso F, Costa A, Norton L et al (2012) 1st International Consensus Guidelines for advanced breast cancer (ABC 1). Breast 21:242–252PubMedCrossRef Cardoso F, Costa A, Norton L et al (2012) 1st International Consensus Guidelines for advanced breast cancer (ABC 1). Breast 21:242–252PubMedCrossRef
13.
go back to reference Cardoso F, Bedard PL, Winer EP, ESO-MBC Task Force et al (2009) International guidelines for management of metastatic breast cancer: combination vs sequential single-agent chemotherapy. J Natl Cancer Inst 101:1174–1181PubMedCentralPubMedCrossRef Cardoso F, Bedard PL, Winer EP, ESO-MBC Task Force et al (2009) International guidelines for management of metastatic breast cancer: combination vs sequential single-agent chemotherapy. J Natl Cancer Inst 101:1174–1181PubMedCentralPubMedCrossRef
14.
go back to reference Kohno N (2008) Treatment of breast cancer with bone metastasis: bisphosphonate treatment—current and future. Int J Clin Oncol 13:18–23PubMedCrossRef Kohno N (2008) Treatment of breast cancer with bone metastasis: bisphosphonate treatment—current and future. Int J Clin Oncol 13:18–23PubMedCrossRef
15.
go back to reference Akhtari M, Mansuri J, Newman KA, Guise TM, Seth P (2008) Biology of breast cancer bone metastasis. Cancer Biol Ther 7:3–9PubMedCrossRef Akhtari M, Mansuri J, Newman KA, Guise TM, Seth P (2008) Biology of breast cancer bone metastasis. Cancer Biol Ther 7:3–9PubMedCrossRef
16.
17.
go back to reference Rose AA, Siegel PM (2010) Emerging therapeutic targets in breast cancer bone metastasis. Future Oncol 6:55–74PubMedCrossRef Rose AA, Siegel PM (2010) Emerging therapeutic targets in breast cancer bone metastasis. Future Oncol 6:55–74PubMedCrossRef
18.
go back to reference Fumoleau P, Largillier R, Clippe C et al (2004) Multicentre, phase II study evaluating capecitabine monotherapy in patients with anthracycline- and taxane-pretreated metastatic breast cancer. Eur J Cancer 40:536–542PubMedCrossRef Fumoleau P, Largillier R, Clippe C et al (2004) Multicentre, phase II study evaluating capecitabine monotherapy in patients with anthracycline- and taxane-pretreated metastatic breast cancer. Eur J Cancer 40:536–542PubMedCrossRef
19.
go back to reference Geels P, Eisenhauer E, Bezjak A, Zee B, Day A (2000) Palliative effect of chemotherapy: objective tumor response is associated with symptom improvement in patients with metastatic breast cancer. J Clin Oncol 18:2395–2405PubMed Geels P, Eisenhauer E, Bezjak A, Zee B, Day A (2000) Palliative effect of chemotherapy: objective tumor response is associated with symptom improvement in patients with metastatic breast cancer. J Clin Oncol 18:2395–2405PubMed
20.
go back to reference Ramirez AJ, Towlson KE, Leaning MS, Richards MA, Rubens RD (1998) Do patients with advanced breast cancer benefit from chemotherapy? Br J Cancer 78:1488–1494PubMedCentralPubMedCrossRef Ramirez AJ, Towlson KE, Leaning MS, Richards MA, Rubens RD (1998) Do patients with advanced breast cancer benefit from chemotherapy? Br J Cancer 78:1488–1494PubMedCentralPubMedCrossRef
21.
go back to reference Costa L, Major PP (2009) Effect of bisphosphonates on pain and quality of life in patients with bone metastases. Nat Clin Pract Oncol 6:163–174PubMedCrossRef Costa L, Major PP (2009) Effect of bisphosphonates on pain and quality of life in patients with bone metastases. Nat Clin Pract Oncol 6:163–174PubMedCrossRef
22.
go back to reference Oura S, Hirai I, Yoshimasu T, Kokawa Y, Sasaki R (2003) Clinical efficacy of bisphosphonate therapy for bone metastasis from breast cancer. Breast Cancer 10:28–32PubMedCrossRef Oura S, Hirai I, Yoshimasu T, Kokawa Y, Sasaki R (2003) Clinical efficacy of bisphosphonate therapy for bone metastasis from breast cancer. Breast Cancer 10:28–32PubMedCrossRef
Metadata
Title
A cross-sectional survey of the diagnosis and management of bone metastasis in breast cancer patients in Turkey
Authors
Ali Arican
Tulin Bozkurt
Hakan Bozcuk
Binnaz Demirkan
Suleyman Buyukberber
Necati Alkis
Ulus Ali Sanli
Celalettin Camci
Mustafa Yildiz
Idris Yucel
Kazim Uygun
Isik Aslay
Mutlu Demiray
Nuran Senel Bese
Abdurrahman Isikdogan
Zumrut Bahat
Cengiz Gemici
Feyyaz Ozdemir
Fatih Ozdener
Bahadir Pekin
Publication date
01-10-2014
Publisher
Springer Berlin Heidelberg
Published in
Supportive Care in Cancer / Issue 10/2014
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-014-2253-9

Other articles of this Issue 10/2014

Supportive Care in Cancer 10/2014 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine